Questcor Pharmaceuticals Inc  

(Public, NASDAQ:QCOR)   Watch this stock  
Find more results for QCOR
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 47.71 - 97.80
Open     -
Vol. 0.00
Mkt cap 5.75B
P/E 0.00
Div/yield     -/∞T
EPS 5.72
Shares 61.45M
Beta 0.98
Inst. own 104%
Oct 27, 2014
Q3 2014 Questcor Pharmaceuticals Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 34.59% 36.63%
Operating margin 52.99% 55.05%
EBITD margin - 56.92%
Return on average assets 44.56% 59.19%
Return on average equity 74.61% 104.28%
Employees 324 -
CDP Score - -


1300 N Kellogg Dr Ste D
ANAHEIM, CA 92807-1965
United States - Map
+1-714-7864200 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Questcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. The Company is focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Its primary product is H.P. Acthar Gel (repository corticotropin injection), or Acthar, an injectable drug that is approved by the United States food and drug administration (FDA), for the treatment of 19 indications. Its research and development program is focused on: the evaluation of the use of Acthar for certain on-label indications; the investigation of other potential uses of Acthar for indications not FDA approved; and the expansion of its understanding of how Acthar works in the human body (pharmacology), and ultimately, its mechanisms of action in the disease states for which it is used, or may be used in the future. In August 2014, Mallinckrodt Plc acquired Questcor Pharmaceuticals, Inc.